Bristol-Myers urges shareholders to support $74 billion Celgene deal

Bristol-Myers Squibb on Wednesday urged investors to support its $74 billion purchase of cancer drugmaker Celgene amid public resistance from top shareholders.

Source link

Leave a Comment

OxyContin maker Purdue Pharma loses bid to delay opioid epidemic trialNutrient supplement 'boosts growth of breastfed premature babies'